735 related articles for article (PubMed ID: 24012693)
1. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma.
Korita PV; Wakai T; Shirai Y; Matsuda Y; Sakata J; Cui X; Ajioka Y; Hatakeyama K
Hum Pathol; 2008 Dec; 39(12):1777-83. PubMed ID: 18701136
[TBL] [Abstract][Full Text] [Related]
3. [Abnormal expression of beta-catenin and E-cadherin in Her2-positive breast cancer and its implications].
Niu LG; He JJ; Wang K; Zhang W; Zhou C
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2237-40. PubMed ID: 19923077
[TBL] [Abstract][Full Text] [Related]
4. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.
Grönberg M; Fjällskog ML; Jirström K; Janson ET
Acta Oncol; 2012 Mar; 51(3):386-93. PubMed ID: 22067021
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
6. Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma.
Kim HS; Kim GY; Kim YW; Park YK; Song JY; Lim SJ
Histopathology; 2010 May; 56(6):708-19. PubMed ID: 20546336
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
[TBL] [Abstract][Full Text] [Related]
9. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer.
Yoshida R; Kimura N; Harada Y; Ohuchi N
Int J Oncol; 2001 Mar; 18(3):513-20. PubMed ID: 11179480
[TBL] [Abstract][Full Text] [Related]
10. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of β-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer.
Xu L; Jiang Y; Zheng J; Xie G; Li J; Shi L; Fan S
Hum Pathol; 2013 Jul; 44(7):1357-64. PubMed ID: 23375645
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer.
Gonzalez MA; Pinder SE; Wencyk PM; Bell JA; Elston CW; Nicholson RI; Robertson JF; Blamey RW; Ellis IO
J Pathol; 1999 Apr; 187(5):523-9. PubMed ID: 10398116
[TBL] [Abstract][Full Text] [Related]
16. Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome.
Goyal A; Martin TA; Mansel RE; Jiang WG
World J Surg Oncol; 2008 Jun; 6():56. PubMed ID: 18547424
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
18. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
20. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.
Rakha EA; Abd El Rehim D; Pinder SE; Lewis SA; Ellis IO
Histopathology; 2005 Jun; 46(6):685-93. PubMed ID: 15910600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]